Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Author index

Page Path
HOME > Browse articles > Author index
Search
Joseph D. Feuerstein 1 Article
IBD
Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein
Intest Res 2022;20(1):72-77.   Published online February 3, 2021
DOI: https://doi.org/10.5217/ir.2020.00117
AbstractAbstract PDFPubReaderePub
Background/Aims
Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn’s disease (CD). However, even with earlier usage of biologic therapy, a significant proportion of patients will require surgery. Vedolizumab is an anti-integrin antibody that is increasingly used given that it is more gut selective and associated with fewer side effects. The aim of this study is to assess the effect of vedolizumab compared to anti-tumor necrosis factor (anti-TNF) therapy on the perioperative complications in patients undergoing surgery for inflammatory bowel disease (IBD).
Methods
Retrospective review of patients treated for IBD at a tertiary care center between 2013 and 2017. Rates of 30- and 90-day complications for patients on vedolizumab were compared to patients on anti-TNF regimens.
Results
One hundred and ninety-nine patients met inclusion criteria with 87 (43%) patients undergoing surgery for CD, 111 (55.8%) for UC and 1 (0.5%) for indeterminate colitis. Thirty-eight patients received preoperative vedolizumab and 94 received anti-TNF. There were more males and lower body mass index in the anti-TNF group. There was no significant difference in overall rate of complications at 30 or 90 days. There was a trend for lower leak rate vedolizumab group (0% for vedolizumab vs. 2.1% for anti-TNF at 30 days, P= 1.00; 0% for vedolizumab vs. 1.1% for anti-TNF at 90 days, P= 1.00). Multivariate analysis showed low albumin ( < 3.6 g/dL) at the time of surgery to be a significant risk factor for overall and infectious complications at 90 days (odds ratio, 3.24; 95% confidence interval, 1.12–8.79; P= 0.021).
Conclusions
Perioperative vedolizumab does not increase rates of perioperative complications in IBD surgery when compared to anti-TNF medications.

Citations

Citations to this article as recorded by  
  • Safety and Monitoring of Inflammatory Bowel Disease Advanced Therapies
    Shubha Bhat, Benjamin Click, Miguel Regueiro
    Inflammatory Bowel Diseases.2024; 30(5): 829.     CrossRef
  • Newer Immunosuppressants for Rheumatologic Disease
    Ye Rin Koh, Kenneth C. Cummings
    Anesthesiology Clinics.2024; 42(1): 131.     CrossRef
  • Peri-Operative Optimization of Patients with Crohn’s Disease
    Hareem Syed, Ahmed Nadeem, David Gardinier, Kendra Weekley, Dovid Ribakow, Stephen Lupe, Shubha Bhat, Stefan Holubar, Benjamin L. Cohen
    Current Gastroenterology Reports.2024; 26(5): 125.     CrossRef
  • Clinical Significance of Prognostic Nutrition Index in Patients with Crohn’s Disease after Primary Bowel Resection
    Hyeon Woo Bae, Yong Joon Lee, Min Young Park, Seung Yoon Yang, Yoon Dae Han, Min Soo Cho, Hyuk Hur, Kang Young Lee, Jae Hee Cheon, Joseph C. Carmichael, Byung Soh Min
    Yonsei Medical Journal.2024; 65(7): 380.     CrossRef
  • Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study
    Gabriele Dragoni, Tommaso Innocenti, Aurelién Amiot, Fabiana Castiglione, Laura Melotti, Stefano Festa, Edoardo Vincenzo Savarino, Marie Truyens, Konstantinos Argyriou, Daniele Noviello, Tamas Molnar, Vincent Bouillon, Cristina Bezzio, Piotr Eder, Samuel
    American Journal of Gastroenterology.2024; 119(8): 1525.     CrossRef
  • Newer Immunosuppressants for Rheumatologic Disease
    Ye Rin Koh, Kenneth C. Cummings
    Rheumatic Disease Clinics of North America.2024; 50(3): 545.     CrossRef
  • Full Guidelines—From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis
    Warren A. James, Angela L. Rosenberg, Jashin J. Wu, Sylvia Hsu, April Armstrong, Elizabeth B. Wallace, Lara Wine Lee, Joseph Merola, Sergio Schwartzman, Dafna Gladman, Clive Liu, John Koo, Jason E. Hawkes, Soumya Reddy, Ron Prussick, Paul Yamauchi, Michae
    Journal of the American Academy of Dermatology.2024; 91(2): 251.e1.     CrossRef
  • Tofacitinib Exposure Does Not Increase Postoperative Complications Among Patients With Ulcerative Colitis Undergoing Total Colectomy: A Retrospective Case–Control Study
    Ibrahim Gomaa, Sara Aboelmaaty, Himani Bhatt, Robert A. Vierkant, Sherief F. Shawki, David W. Larson, Kevin T. Behm, Kristen K. Rumer
    Diseases of the Colon & Rectum.2024; 67(11): 1443.     CrossRef
  • An update on the safety of long-term vedolizumab use in inflammatory bowel disease
    Sailish Honap, Patrick Netter, Silvio Danese, Laurent Peyrin-Biroulet
    Expert Opinion on Drug Safety.2023; 22(9): 767.     CrossRef
  • Perioperative Management of Pediatric Crohn’s Disease
    Brad Pasternak, Ashish Patel, Paul Tran, Lisa McMahon
    Journal of Pediatric Gastroenterology & Nutrition.2023; 76(2): 137.     CrossRef
  • Perioperative Assessment and Optimization in Major Colorectal Surgery: Medication Management
    William J. Kane, Puja Shah Berry
    Clinics in Colon and Rectal Surgery.2023; 36(03): 210.     CrossRef
  • Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?
    Jihye Park
    Intestinal Research.2022; 20(1): 1.     CrossRef
  • Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
    Soo-Young Na, You Sun Kim
    The Korean Journal of Internal Medicine.2022; 37(5): 906.     CrossRef
  • Anti -TNFα agents in preventing the postoperative recurrence of Crohn’s disease: Do they still play a role in the biological era?
    Caiguang Liu, Na Li, Shukai Zhan, Zhenyi Tian, Dongxuan Wu, Tong Li, Zhirong Zeng, Xiaojun Zhuang
    Expert Opinion on Biological Therapy.2021; : 1.     CrossRef
  • 5,996 View
  • 385 Download
  • 12 Web of Science
  • 14 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP